



Investor Presentation

Venus Medtech 2021 Annual Report



Disclaimer

By attending the meeting where this presentation is made, or by reading the presentation materials, you agree to be bound by the following limitations:

The information in this presentation has been prepared by representatives of Venus Medtech(Hangzhou) Inv. (the "Company") for use in presentation by the company at investor meetings for information purposes. No part of this presentation should form the basis of, or be relied on in connection with, any contract or commitment or investment decision whatsoever.

No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information, or opinions contained herein. Neither the Company nor any of its directors, supervisors, officers, partners, employees, affiliates, agents, advisors or representatives shall have any responsibility or liability whatsoever (for negligence or otherwise) for any loss howsoever arising from any use of this presentation or its contents or otherwise arising in connection with this presentation. The information set out herein may be subject to updating, completion, revision, verification and amendment and such information may change materially.

This presentation is based on the economic, regulatory, market and other conditions as in effect on the date hereof. It should be understood that subsequent developments may affect the information contained in this presentation, which neither the Company nor any of its directors, supervisors, officers, partners, employees, affiliates, agents, advisors or representatives is under an obligation to update, revise or affirm.

The information communicated in this presentation contains certain statements that are or may be forwarding-looking. These statements typically contain words such as "will" "may" "expert" "forecast" "plan" and "anticipate" and words of similar import. By their nature forward-looking statement involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There may be additional material risks that are currently not considered to be material or of which the Company and its advisors or representatives are unaware. Against the background of these uncertainties, readers should not rely on these forward-looking statements. The Company assumes no responsibility to update the forward-looking statements or to adapt them to future events or developments.

This presentation and the information contained herein does not constitute or form part of any offer to sale or subscription of or solicitation or invitation of any offer to buy or subscribe for any securities of the Company in any jurisdiction. This presentation and the information contained herein is highly confidential and being furnished to you solely for your information and may not be reproduced or redistributed in any manner to any other person, in whole or in part. In particular, neither the information contained in this presentation nor any copy hereof may be, directly or indirectly, taken or transmitted into or in the United States, Canada, Australia, Japan, Hong Kong or any other jurisdiction which prohibits the same except in compliance with applicable securities laws. Any failure to comply with this restriction may constitute a violation of U.S. or other national securities laws. No money, securities or other consideration is being solicited, and, if sent in response to this presentation or the information contained herein, will be accepted.

By attending this presentation, you acknowledge that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the business of the Company. Any decision to purchase securities in the context of a proposed offering of securities, if any, should be made solely on the basis of information contained in an offering circular or prospectus prepared in relation to such offering.

By reviewing this presentation, you are deemed to have represented and agreed that you and any customers you represent are neither (i) a "qualified institutional buyer" (within the meaning of Rule 14A under the United States Securities Act of 1933, as amended), or (ii) outside the United States. You are also deemed to have represented and agreed that you and any customers you represent are professional investors as defined in the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and any rules made thereunder.

Content

01

Business Highlights

02

Commercial Review

03

Global Innovation

01 Business Highlights

Business Highlights

Covering Structural Heart Diseases

3 Registration
Application

VenusP-Valve, TriGUARD3, VenusA-Pro

5 Clinical Trials

Cardiovalve, Liwen RF, Vitae, PowerX, Leaflex

Continue R&D and key product trials

- **4 Expected to enter into clinical trials:**
Cardiovalve(China), Liwen RF(Europe), Venus-Neo, RDN
- **3 Expected to be launched products:**
VenusP-Valve, TriGUARD3, VenusA-Pro

Leading the Chinese TAVR Market

- ✓ Full-year revenue **RMB416 million**, YOY up **50.6%**
- ✓ 2021 procedure volume grew to **3600**
- ✓ Covering hospital **360**, sales person **220**
- ✓ Overseas sales revenue RMB10.51million, YOY up **160.5%**


Continue to Lead the Market

- Maintaining market share **60%~65%**
- Hospital coverage **400** above
- Sales team **300** above

02 Commercial Performance


Financial Review

Sales Revenue




Unit: million RMB

China Revenue



Unit: million RMB

Overseas Revenue



Unit: million RMB

Largest Share of Market in China



2021 procedure volume **3600**

VenusA-Plus occupied 35% volume

Hospital covered 360

Sales person reached 220

Cumulative procedure **9000+**



Top-tier hospitals volume grow steadily
Mid-tier hospitals volume increase sharply

*Data source

1. China National Center for Cardiovascular Diseases (20220114)
2. Chinese Journal of Interventional Cardiology, 2022, 30 (1)
3. Company data

TAVR Training and Education



【TAVR Master Series】

Master Show& Master Talk:


Held over 10 activities including live broadcast、seminars



【2021 Season 2 Venus X Factor】

Focus on difficult and complicated TAVR cases
Work with national experts in structural heart
Promote high-quality development of TAVR

Overseas sales grow steadily



2021 overseas revenue



Sales 10.51
million RMB




Growth Rate
160.5%


Overseas sales team expanded, **VenusP-Valve** was approved on April 8th in Europe

03 Global Innovation

Heart Valve Product Pipeline









In Jan 2022, Venus Medtech acquired Cardiovalve, a Israeli company and established the Venus Global Heart Valve Innovation Center in Israel to leverage Cardiovalve technology platform and develop a new generation of AR valve.



Feature

- Fits both MR & TR
- Dual frame self-expanding Nitinol
- Valve design modeled on an established surgical mitral valve, aiming to provide a low ventricular profile, minimizing LVOTO risk, potentially providing more durability
- Through transfemoral access

Global TMVR Products Comparison

Product	Figure	Delivery	Size	Clinical Studies	Anchoring
Cardiovalve CARDIOVALVE		Transfemoral	28F	EU&U.S. EFS	Mitral valve leaflets/annulus
Cephea 		Transfemoral	32F	FIM	Mitral valve leaflets/annulus
Intrepid Medtronic		Transapical/ Transfemoral	35F	EFS	Perimeter oversizing
Tendyne 		Transapical	34-36F	CE Mark 2020	Apical pad

Cardiovalve Initial Clinical Results

90% secondary MR pts, **80%** pts with heart failure hospitalization in past year

Baseline Characteristics (N=11)			
Age (years)	73±6.2	Etiology	
STS (Avg, Min, Max)	7 (2,16)	Secondary MR	90% (10)
NYHA III/IV	90% (10)	Mixed	10% (1)
Prior HF Hospitalization in past year (%)	80% (9)	Severe MR	100% (11)
Prior cardiovascular surgery (%)	45% (5)	Atrial Fibrillation(%)	77.2% (8)

The occurrence rate of LVOT obstruction in TMVR 9.3%*, Cardiovalve post-operation LVOT obstruction 0%; procedure completed 100%

Procedure Parameters (N=11)	
LVOT Obstruction (%)	0% (0)
Procedure Completed(Device Implanted) (%)	100%


*Core Lab assessment

Source: TMVR introduction and challenges (I) , AP-SHD, 20190916

Cardiovalve Initial Clinical Results

Before: 100% pts \geq Moderate MR

After: immediate 100% pts \leq Mild MR, 30 days 76% pts maintain \leq Mild MR



Global Clinical Trial Progress Rapidly




TR

- Completed successfully implantation in **13** patients (compassionate route in Canada, Italy and Germany)
- EFS in Europe ongoing
- EFS in US in preparation, approved as a breakthrough designated therapy

MR

- Completed successfully a clinical study in **11** patients, the longest follow-up, of the first patient, is approaching **4** years
- AHEAD EU study commenced in **5** European Countries
- AHEAD US EFS study in preparation


On December 2021,Venus-PowerX completed its First-in-Man clinical trial at West China Hospital of Sichuan University.



Feature


- Self-expanding TAVR
- Active anti-paravalvular leak technology
- Dry tissue for storage and reduced glutaraldehyde
- Anti-calcification technology, long-term durability
- 100% retrieving

On December 16, 2021 the Company successfully completed the first two implantations in the First-in-Man clinical trial at Instituto De Cardiologia Hospital in Argentina.



Feature

- Balloon-expandable TAVR
- Valve lock wire design ensures accurate positioning and deployment
- Supra-annular prosthesis design
- Dry tissue for durability, storage and calcification reduction



Feature


- The only Chinese pulmonic valve product used in Europe and Americas
- the first self-expanding pulmonic valve product approved for marketing in Europe
- Included in the “Special Review Procedure for Innovative Medical Devices” by NMPA, registration application under review in China
- In Mar 2021, Special Use granted by the U.K. MHRA and sales in some designated hospitals in U.K.
- On April 8th, obtained CE Marking under MDR

VenusP-Valve 2 Year Follow-up Results

Clinical trial results show “0” occurrence of death or reoperation

Procedural success	79(100%)
Mortality rate at 6-month	0%
Mortality rate at 12-month	0%
Mortality rate at 2-year	0%


Procedural success	79(100%)
Re-operation rate at 6-month	0%
Re-operation rate at 12-month	0%
Re-operation rate at 2-year	0%



VenusP-Valve 2 Year Follow-up Results


Before: 100% ≥ Moderate PR, After: 1 Year 100% ≤ Mild PR, 2 Year 98.56% ≤ Mild PR

Pulmonic Regurgitation (PR)



Liwen RF Ablation System

In Sep 2021, Venus Medtech entered into share transfer agreement to acquire the shares of Hangzhou Nuocheng Medical Technology Co.,Ltd to obtain its Liwen RF ablation system for treatment of hypertrophic cardiomyopathy.



Feature

- Global novel HCM treatment: echocardiography-guided percutaneous intramyocardial septal radiofrequency ablation
- Compared with surgical myectomy and alcohol septal ablation, less invasive, short recovery, less damage to conduction system, lower recurrence rate and mortality rate
- Controlled ablation power and range, complete ablation

Multi-center Clinical Trial ongoing



Leading Teams

Professor Junbo Ge, Professor Yun Zhang lead the clinical study



Principal Investigator

Professor Liwen Liu, the inventor of Liwen is the PI of the study



Medical Centers

28 centers planned , **21** centers active, including Xijing Hospital, Zhongshan Hospital at Fudan University etc.



Efficacy

Clinical trial ongoing,
11 patients finished 1 month follow-up, success rate **100%**




RDN Ultrasound Ablation

In June 2021, Venus Medtech formed a joint venture company with Healium, an Israeli high technology company, to introduce and R&D, manufacture and commercialize RDN innovative system worldwide.




Non-contact ablation can be used in the treatment of pulmonary hypertension

Continuous Rotation



Step by Step Rotation



Global Intellectual Properties Portfolio

Ranking the 1st in numbers

Until Feb 28 2022,
there are **756** patent
application and **315**
issued patents

Wide coverage

IP covers China, U.S.,
Europe, Japan, Canada,
Russia, India, Brazil
75% invention patents

In-depth layout

Detailed IP portfolio in
key technology such as
latest dry-tissue,
balloon expandable
valve, anti-paravalvular
leak technology.

U.S. R&D Center

Hangzhou R&D Center

Israel R&D Center

Risk Control

Comprehensive risk
control of the entire
life cycle of products

 IP Covered

Thanks!

